Last $1.40 USD
Change Today -0.02 / -1.41%
Volume 164.8K
SIGA On Other Exchanges
As of 8:10 PM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

siga technologies inc (SIGA) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/18/14 - $3.56
52 Week Low
09/16/14 - $0.99
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SIGA TECHNOLOGIES INC (SIGA)

siga technologies inc (SIGA) Related Businessweek News

No Related Businessweek News Found

siga technologies inc (SIGA) Details

SIGA Technologies, Inc. is engaged in the development and commercialization of pharmaceutical solutions for serious unmet medical needs and biothreats. The company’s lead product is Arestvyr, an orally administered antiviral drug that targets orthopoxviruses. It is also developing dengue antiviral and anti-arenavirus drug candidates, which are in pre-clinical stage. SIGA Technologies, Inc. was founded in 1995 and is headquartered in New York, New York. On September 16, 2014, SIGA Technologies, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of New York.

34 Employees
Last Reported Date: 03/10/14
Founded in 1995

siga technologies inc (SIGA) Top Compensated Officers

Executive Chairman, Chief Executive Officer a...
Total Annual Compensation: $1.1M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $636.5K
Chief Scientific Officer and Vice President
Total Annual Compensation: $772.5K
Executive Vice President and General Counsel
Total Annual Compensation: $675.0K
Compensation as of Fiscal Year 2013.

siga technologies inc (SIGA) Key Developments

SIGA Technologies, Inc. expected to report Fiscal Year 2014 results on January 29, 2015. This event was calculated by Capital IQ (Created on January 23, 2015).

SIGA Technologies, Inc. expected to report Fiscal Year 2014 results on January 29, 2015. This event was calculated by Capital IQ (Created on January 23, 2015).

Delaware Court of Chancery Issues a Letter Opinion Regarding SIGA Technologies

SIGA Technologies, Inc. announced that on January 7, 2015, the Delaware Court of Chancery, acting on remand from the Delaware Supreme Court, issued a letter opinion in the litigation begun by PharmAthene, Inc. in 2006. The court has directed PharmAthene to submit a revised form of judgment awarding PharmAthene a lump sum of $113,116,985 plus prejudgment interest, costs and fees. SIGA estimates that, including pre-judgment interest through the date of SIGA's chapter 11 filing, the final judgment will be approximately $190,000,000. This opinion implements the court's August 8, 2014 decision on remand to reverse its own earlier findings that expectation damages are speculative, conditional and conjectural and, instead, to allow lump sum expectation damages based on hypothetical U. S. Government purchases of SIGA's smallpox drug in 2010 to 2015 that were supposedly anticipated in 2006. SIGA continues to believe the decision to enter the new judgment is not supported by the record or the law and intends to appeal to the Supreme Court of Delaware. Either party may appeal the portions of the trial court rulings that were unfavorable to that party within 30 days of entry of judgment by the court. SIGA currently intends to appeal the judgment, but no assurance can be given that any such appeal will be successful.

SIGA Technologies’ Common Stock To Be Delisted From Nasdaq

On September 16, 2014, SIGA Technologies, Inc. received correspondence from The NASDAQ Stock Market, LLC (Nasdaq) that its staff, after reviewing the announcement by SIGA that it had commenced the Chapter 11 Case, determined that SIGA’s securities will be delisted from the Nasdaq Stock Market and that, unless SIGA requests an appeal of this determination pursuant to the procedures set forth in the Nasdaq Listing Rules, trading of SIGA’s common stock will be suspended at the opening of business on September 25, 2014, and Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission which will remove SIGA’s securities from listing and registration on The Nasdaq Stock Market. The determination of Nasdaq was pursuant to Listing Rules 5101, 5110(b), and IM-5101-1. SIGA anticipates requesting an appeal of the determination of Nasdaq pursuant to the Nasdaq Listing Rules. SIGA’s common stock will remain listed on the Nasdaq Global Market pending the outcome of the hearing.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SIGA:US $1.40 USD -0.02

SIGA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SIGA.
View Industry Companies

Industry Analysis


Industry Average

Valuation SIGA Industry Range
No financial data is available for SIGA.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SIGA TECHNOLOGIES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at